Caraco Pharmaceutical Laboratories
Detroit-based Caraco Pharmaceutical Laboratories Inc. will shortly cease operation as a publicly traded company.
The Detroit generic drug maker Caraco Pharmaceutical reported a loss of $3 million or eight cents a share in the third fiscal quarter of its fiscal year, ended Dec. 31, an improvement from a loss of $3.3 million or eight cents a share in the same quarter a year earlier despite a decline in revenue in the quarter to $40.4 million from $52 million a year earlier.
Detroit-based Caraco Pharmaceutical Laboratories Ltd. (NYSE Amex: CPD) announced last week that G. P. Singh Sachdeva will assume the position of CEO following the resignation of Jitendra N. Doshi as interim CEO and director as […]
Detroit-based Caraco Pharmaceutical Laboratories Ltd. (NYSE Amex: CPD) announced that it has started shipping azelastine ophthalmic solution, 0.05 percent, and rivastigmine tartrate capsules.